Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500989 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL1318390 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3033289 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3031676 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3033285 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL3031679 | 1.00 | GABRR1 (0.35) | GABRR1GABRR2DPP7CPN1CPB2 | |
| SCHEMBL16977621 | 0.84 | EPHX2 (0.34) | DPP7GAADPP4 | |
| SCHEMBL3025369 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 | |
| SCHEMBL3025364 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 | |
| SCHEMBL1314601 | 0.83 | CYP46A1 (0.34) | GAACYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| EP-1641782-B1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-03 | — | — | EP | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-7652040-B2 | gastrointestinal disorders hypermotility, irritable bowel syndrome, constipation or diarrhea | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-1638961-B1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-18 | — | — | EP | disclosed |
| US-7498347-B2 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| EP-1638959-B1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2007-09-19 | — | — | EP | disclosed |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-23 | — | — | US | disclosed |
| EP-1638959-A1 | 5HT -4 -ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1140915-B1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005003122-A1 | 5HT4-ANTAGONISTIC 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003124-A1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003121-A1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000837-A1 | AMINOSULFONYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | WO | disclosed |
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-09-25 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1140915-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037461-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181456-A1 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | HRH2, ALK, CBR1 | GABRR1 93/4885GABRR2 137/4885DPP7 1197/4885 |
| US-20070197600-A1 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists | HTR4, HTR2B, HTR5A | GABRR1 494/4885GABRR2 435/4885DPP7 1110/4885 |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | HTR4, HTR2B, HTR2C | GABRR1 638/4885GABRR2 538/4885DPP7 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.